Zibotentan for the treatment of castrate-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Zibotentan for the treatment of castrate-resistant prostate cancer.

Zibotentan for the treatment of castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q37760222

about

The PCa Tumor Microenvironment.Cancer to bone: a fatal attraction.Endothelin and hepatic wound healing.Current treatment strategies for castration-resistant prostate cancer Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.Molecular Approaches To Target GPCRs in Cancer Therapy.Q57134631

P2860

Q35603143-3F1B9646-BEF3-4898-8456-55DDD521080F Q36884628-FC5877AB-E15B-4710-97CC-4981F99B34F4 Q37855219-9E745330-A9E1-4B43-B4AA-E3EC1BBA7E5B Q37860950-D788A137-9FF1-4CA3-BFD0-64B589E9DC4F Q37868056-01478EE9-CBFC-4EE7-90BF-CF54B32D80BB Q46850333-BEFF1DB7-862F-40FB-AAED-30ABADD217D9 Q57134631-9760D9B8-41A6-4D97-A4CF-6BF3C01F2560

P2860

Zibotentan for the treatment of castrate-resistant prostate cancer.

http://www.wikidata.org/entity/Q37760222

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Zibotentan for the treatment of castrate-resistant prostate cancer.

@en

Zibotentan for the treatment of castrate-resistant prostate cancer.

@nl

type

label

Zibotentan for the treatment of castrate-resistant prostate cancer.

@en

Zibotentan for the treatment of castrate-resistant prostate cancer.

@nl

prefLabel

Zibotentan for the treatment of castrate-resistant prostate cancer.

@en

Zibotentan for the treatment of castrate-resistant prostate cancer.

@nl

P1433

Q37760222-DEBF13F9-F1D0-45A7-82B6-6C28AC91B88D

P1476

Q37760222-3346E402-4E35-4DC9-BF60-975D8A85159E

P2093

Q37760222-A7F41F6F-F0C7-4F80-91D8-88ACCEE8FDF9

Q37760222-DF86BDD9-B6D7-4EF4-BDFD-337E95EB8C3E

P2860

Q37760222-0C2653CA-9C17-426A-8F6C-1E11EF372F81

Q37760222-0C9B41A0-AE55-4A52-A029-792B1CD0F82F

Q37760222-0D59B6B0-846E-4A24-AAEE-F5FEE65AEA0A

Q37760222-1352D25F-AACF-46D1-A16F-9D99E29B5F3E

Q37760222-1FFF24C9-1B04-4217-B098-A7AA2C8070FE

Q37760222-202B9E17-A666-49F8-BC2C-ECAA0A8A77CD

Q37760222-482F6276-0CC7-4972-BAD1-D8ABD2FAC38F

Q37760222-4A40EEE2-0759-40AD-9372-FCA92E5EEA3B

Q37760222-596EAD0C-1219-4BD6-BF1A-4E736E727A7B

Q37760222-61419341-FE2C-4F22-844F-7AC6EAFC312B

P304

Q37760222-16A26BA6-14A9-45CD-A31C-C1452DEFB457

P31

Q37760222-A0825BE4-41B2-437B-A89A-FEF3188AA59A

P356

Q37760222-03A973CE-8891-4F51-8B32-2C28A4886E17

P407

Q37760222-E1448345-54FE-4043-86F0-1DF33854729C

P433

Q37760222-8CD3A84B-292E-47BA-A51D-7DC5DB2489A6

P478

Q37760222-3569E9C0-5447-49E1-9935-5C0A6FFD6C3C

P577

Q37760222-C4108581-72C5-493A-BFBA-DA500FACEBD1

P698

Q37760222-0ADA4E06-5E5F-470A-BF62-108532AA6CB4

P356

13543784.2010.491822

P1433

Expert Opinion on Investigational Drugs

P1476

Zibotentan for the treatment of castrate-resistant prostate cancer.

@en

P2093

Dale R Shepard

http://www.w3.org/2001/XMLSchema#string

Robert Dreicer

http://www.w3.org/2001/XMLSchema#string

P2860

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

Cancer statistics, 2009

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

P304

899-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2010.491822

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20497097

http://www.w3.org/2001/XMLSchema#string